# Contents

1 Neurodegeneration in Neural Trauma, Neurodegenerative Diseases, and Neuropsychiatric Disorders ............................................................... 1
   1.1 Introduction ........................................................................................................... 1
   1.2 Neurodegeneration in Ischemic Injury ................................................................. 7
   1.3 Neurodegeneration in Traumatic Brain Injury and Spinal Cord Trauma ............... 9
   1.4 Neurodegeneration in Neurodegenerative Diseases ............................................. 9
   1.5 Neurodegeneration in Neuropsychiatric Diseases ............................................. 14
   1.6 Similarities and Differences Between Ischemic, Neurotraumatic Injuries, Neurodegenerative Diseases, and Neuropsychiatric Disorders .............. 15
   1.7 Conclusion .......................................................................................................... 20
References .................................................................................................................. 21

2 Neurochemical Aspects of Ischemic Injury ................................................................. 27
   2.1 Introduction .......................................................................................................... 27
   2.2 Ischemic Injury-Mediated Alterations in Glycerophospholipid Metabolism .............. 31
   2.3 Ischemic Injury-Mediated Alterations in Protein Metabolism ................................ 36
   2.4 Ischemic Injury-Mediated Alterations in Nucleic Acid Metabolism ....................... 39
   2.5 Ischemic Injury-Mediated Alterations in Enzymic Activities .................................. 42
   2.6 Ischemic Injury-Mediated Alterations in Nuclear Transcription Factor-κB (NF-κB) .......................................................................................... 43
   2.7 Ischemic Injury-Mediated Alterations in Genes .................................................... 45
   2.8 Ischemic Injury-Mediated Alterations in Cytokines and Chemokines ..................... 48
   2.9 Ischemic Injury-Mediated Alterations in Heat Shock Proteins ............................... 50
   2.10 Ischemic Injury-Mediated Alterations in Adhesion Molecules ............................. 51
   2.11 Ischemic Injury-Mediated Alterations in Apoptosis-Inducing Factor ..................... 52
   2.12 Ischemic Injury-Mediated Alterations in Na\(^+\)/Ca\(^{2+}\) Exchanger ..................... 53
   2.13 Mechanism of Neurodegeneration in Ischemia/Reperfusion Injury ..................... 55
3 Potential Neuroprotective Strategies for Ischemic Injury ........................... 67
3.1 Introduction .................................................................................................. 67
3.2 Potential Treatment Strategies for Ischemic Injuries ................................. 68
   3.2.1 N-Methyl-d-Aspartate Receptor Antagonists and Stroke Therapy ........ 73
   3.2.2 Calcium Channel Blockers and Stroke Therapy ................................... 74
   3.2.3 Free Radical Scavengers and Stroke Therapy ....................................... 74
   3.2.4 GM₁ Ganglioside and Stroke Therapy .................................................. 78
   3.2.5 Statins and Stroke Therapy ................................................................. 79
   3.2.6 ω-3 Fatty Acids and Stroke .................................................................. 80
   3.2.7 Citicoline (CDP-Choline) and Stroke Therapy ....................................... 82
   3.2.8 Peroxisome Proliferator-Activated Receptor γ-Agonists and Stroke ........ 84
   3.2.9 Hypoxia-Inducible Factor 1 and Stroke Therapy ................................. 85
   3.2.10 Vaccine and Stroke Therapy ............................................................... 86
   3.2.11 Pipeline Developments on Drugs for Stroke Therapy ....................... 87
   3.2.12 Intracellular Cell Therapy in Stroke ................................................... 89
3.3 Mechanism of Neuroprotection in Ischemic Injury ................................. 90
   3.3.1 Prevention of Stroke Through the Modulation of Risk Factors ............... 92
   3.3.2 Selection of Diet and Stroke .................................................................. 92
   3.3.3 Physical Exercise and Stroke ................................................................ 95
   3.3.4 Transcranial Magnetic Stimulation and Stroke Rehabilitation ................ 96
   3.3.5 Occupational Therapy and Rehabilitation After Stroke ...................... 97
3.4 Conclusion .................................................................................................. 98
References ......................................................................................................... 99

4 Neurochemical Aspects of Spinal Cord Injury ............................................. 107
4.1 Introduction ............................................................................................... 107
4.2 Regeneration and Neuritogenesis in SCI .................................................... 109
4.3 Necrosis and Apoptosis in SCI ................................................................. 111
4.4 Contribution of Excitotoxicity in Spinal Cord Injury ............................... 112
4.5 Enzymic Activities in Spinal Cord Injury .................................................. 114
   4.5.1 Activation of PLA₂ in Spinal Cord Injury ............................................ 114
   4.5.2 Activation of COX-2 in Spinal Cord Injury ......................................... 116
   4.5.3 Activation of NOS in Spinal Cord Injury ............................................. 117
   4.5.4 Activation of Calcineurin in Spinal Cord Injury ................................... 119
   4.5.5 Activation of Matrix Metalloproteinases in Spinal Cord Injury ............. 119
   4.5.6 Activation of Poly (ADP-Ribose) Polymerase in Spinal Cord Injury ...... 121
   4.5.7 Activation of RhoA and RhoB in Spinal Cord Injury ........................... 122
4.5.8 Activation of Caspases in Spinal Cord Injury 122
4.5.9 Activation of Calpains and Other Proteases in Spinal Cord Injury 123
4.6 Activation of Cytokines and Chemokines in Spinal Cord Injury 124
4.7 Fas/CD95 Receptor–Ligand System in Spinal Cord Injury 126
4.8 Activation of Transcription Factors in Spinal Cord Injury 126
4.8.1 NF-κB in Spinal Cord Injury 127
4.8.2 Peroxisome Proliferator-Activated Receptor in Spinal Cord Injury 128
4.8.3 STAT in Spinal Cord Injury 128
4.8.4 AP-1 in Spinal Cord Injury 129
4.9 Gene Transcription in Spinal Cord Injury 130
4.10 Mitochondrial Permeability Transition in Spinal Cord Injury 130
4.12 Growth Factors in Spinal Cord Injury 133
4.13 Other Neurochemical Changes in Spinal Cord Injury 135
4.14 Neuropathic Pain in SCI 136
4.15 Contribution of Oxidative Stress in Spinal Cord Injury 137
4.16 Inflammation in Spinal Cord Injury 139
4.17 Interactions Among Excitotoxicity, Oxidative Stress, and Inflammation in Spinal Cord Injury 140
4.18 Conclusion 141
References 142

5 Potential Neuroprotective Strategies for Experimental Spinal Cord Injury 151
5.1 Introduction 151
5.2 Metalloproteinases and Glial Scar Formation 152
5.3 Other Inhibitory Molecules Contributing to Axonal Growth Inhibition 152
5.4 Neuroprotective Strategies 156
5.4.1 Methylprednisolone and SCI 157
5.4.2 GM1 Ganglioside and SCI 160
5.4.3 Tirilazad Mesylate and SCI 161
5.4.4 Inhibitors of Calpains, Nitric Oxide Synthase, and PLA2 and SCI 162
5.4.5 Minocycline and SCI 165
5.4.6 Thyrotropin-Releasing Hormone and SCI 167
5.4.7 Dantrolene and SCI 167
5.4.8 ω-3 Fatty Acids and SCI 168
5.4.9 Polyethylene Glycol and SCI 168
5.4.10 Opioid Receptor Antagonists, Glutamate Receptor Antagonists, and Calcium Channel Blockers in SCI 169
5.4.11 Growth Factors and SCI 170
5.5 Regeneration and SCI .............................................. 171
  5.5.1 Stem/Progenitor Cell Transplants .......................... 171
  5.5.2 Human Umbilical Cord Blood Stem Cells Transplants .. 172
5.6 Rehabilitation and SCI ........................................... 173
5.7 Conclusion ....................................................... 174
References .......................................................... 174

6 Neurochemical Aspects of Traumatic Brain Injury .............. 183
  6.1 Introduction .................................................... 183
  6.2 TBI-Mediated Alterations in Glutamate and Calcium Levels .. 186
  6.3 TBI-Mediated Alterations in Cytokines ........................ 187
  6.4 TBI-Mediated Alterations in Chemokines ....................... 188
  6.5 TBI-Mediated Alterations in Enzymic Activities ................. 189
    6.5.1 PLA$_2$ and DAG/PLC Pathway in TBI ..................... 190
    6.5.2 Cyclooxygenases (COX) and Lipoxygenases (LOX) in TBI .... 191
    6.5.3 Calpain Activity in TBI ................................... 192
    6.5.4 Caspases in TBI .......................................... 192
    6.5.5 Nitric Oxide Synthase in TBI ............................. 193
    6.5.6 Kinases in TBI ............................................ 194
    6.5.7 Matrix Metalloproteinases (MMPs) in TBI .................. 196
    6.5.8 Calcineurin in TBI ....................................... 196
    6.5.9 Other Enzymes in TBI ..................................... 197
  6.6 TBI-Mediated Alterations in Cytoskeletal Protein ............. 197
  6.7 TBI-Mediated Alterations in Transcription Factors ............ 198
    6.7.1 Nuclear Factor Kappa B (NF-$\kappa$B) in TBI .............. 198
    6.7.2 Signal Transducers and Activators of Transcription (STATs) in TBI ... 200
    6.7.3 Nuclear Factor E2-Related Factor 2 in TBI .............. 200
    6.7.4 AP-1 Transcription Factor in TBI ........................ 201
    6.7.5 CCAAT/Enhancer-Binding Protein (C/EBP) in TBI ......... 201
  6.8 TBI-Mediated Alterations in Gene Expression .................. 202
  6.9 TBI-Mediated Alterations in Adhesion Molecules ............... 204
  6.10 TBI-Mediated Alterations in Neurotrophic Factors ............ 204
  6.11 TBI-Mediated Alterations in Complement System ................ 205
  6.12 TBI Mediators Alterations in Endocannabinoids ............... 206
  6.13 TBI-Mediated Changes in Hydroxycholesterols .................. 207
  6.14 TBI and Apoptotic Cell Death ................................ 207
  6.15 Molecular Mechanism of Neurodegeneration in TBI ............. 208
  6.16 Conclusion ................................................... 210
References .......................................................... 210

7 Potential Neuroprotective Strategies for Traumatic Brain Injury . 219
  7.1 Introduction .................................................... 219
  7.2 Regeneration and Neuritogenesis in TBI ........................ 220
7.3 Potential Neuroprotective Strategies for TBI

7.3.1 Statins and TBI

7.3.2 Progesterone and TBI

7.3.3 Erythropoietin and TBI

7.3.4 Minocycline and TBI

7.3.5 PPARα Agonist and TBI

7.3.6 Endocannabinoids and TBI

7.3.7 Thyrotropin-Releasing Hormone (TRH) and TBI

7.3.8 Cytidine (CDP-Choline) and TBI

7.3.9 ω-3 Fatty Acids and TBI

7.3.10 Hypothermia and TBI

7.4 Cell Therapy and TBI

7.5 Conclusion

References

8 Neurochemical Aspects of Neurodegenerative Diseases

8.1 Introduction

8.2 Factors and Molecular Mechanisms that Modulate Neurodegeneration in Neurodegenerative Diseases

8.3 Neurochemical Aspects of Alzheimer Disease

8.3.1 Lipids in AD

8.3.2 Protein in AD

8.3.3 Nucleic Acid in AD

8.3.4 Transcription Factors in AD

8.3.5 Gene Expression in AD

8.3.6 Neurotrophins in AD

8.3.7 Insulin and Insulin-Like Growth Factor in AD

8.4 Neurochemical Aspects of Parkinson Disease

8.4.1 Lipids in PD

8.4.2 Proteins in PD

8.4.3 Nucleic Acids in PD

8.4.4 Transcription Factors in PD

8.4.5 Gene Expression in PD

8.4.6 Neurotrophins in PD

8.5 Neurochemical Aspects of Amyotrophic Lateral Sclerosis

8.5.1 Lipids in ALS

8.5.2 Proteins in ALS

8.5.3 Nucleic Acids in ALS

8.5.4 Transcription Factors in ALS

8.5.5 Gene Expression in ALS

8.5.6 Neurotrophins in ALS

8.6 Neurochemical Aspects of Huntington Disease

8.6.1 Lipids in HD

8.6.2 Proteins in HD

8.6.3 Nucleic Acids in HD
8.6.4 Transcription Factors in HD ......................... 289
8.6.5 Gene Expression in HD .......................... 290
8.6.6 Neurotrophins in HD ............................. 291
8.7 Neurochemical Aspects of Prion Diseases ............. 292
  8.7.1 Lipids in Prion Diseases .......................... 294
  8.7.2 Proteins in Prion Diseases ......................... 296
  8.7.3 Nucleic Acids in Prion Diseases .................... 297
  8.7.4 Transcription Factors in Prion Diseases .......... 297
  8.7.5 Gene Expression in Prion Diseases ................ 297
  8.7.6 Neurotrophins in Prion Diseases ................... 298
8.8 Complement System Changes and Neurodegenerative Diseases 299
8.9 Apoptotic and Necrotic Cell Death and Autophagy in Neurodegenerative Diseases ..................... 300
8.10 Mechanisms of Neurodegeneration in Neurodegenerative Diseases ................................ 303
8.11 Conclusion ............................................ 307
References .................................................. 308

9 Potential Therapeutic Strategies for Neurodegenerative Diseases .................................. 325
  9.1 Introduction ............................................ 325
  9.2 Factors Influencing the Onset of Neurodegenerative Diseases .................................. 326
    9.2.1 Genetic and Environmental Factors ................ 327
    9.2.2 Lifestyle and Neurodegenerative Diseases ........ 328
    9.2.3 Diet and Neurodegenerative Diseases ............. 330
  9.3 Therapeutic Approaches for AD ........................ 333
    9.3.1 Cholinergic Strategies ............................. 333
    9.3.2 Antioxidant, Anti-inflammatory, and Antiexcitotoxic Strategies in AD ............ 336
    9.3.3 Stabilization of Mitochondrial Dynamics and AD .......................... 337
    9.3.4 Statins and AD Treatment ........................... 339
    9.3.5 Memantine and AD Treatment ......................... 341
    9.3.6 Secretase Inhibitors and AD Treatment .............. 343
    9.3.7 PPAR Agonists and AD Treatment ..................... 344
    9.3.8 Neurotrophins and AD Treatment ..................... 346
    9.3.9 ω-3 Fatty Acids and AD Treatment ................... 347
    9.3.10 Immunization Therapy in AD ......................... 349
    9.3.11 AL-108 or NAP Therapy in AD ...................... 350
  9.4 Therapeutic Approaches for PD ......................... 350
    9.4.1 Dopaminergic Strategies in PD ....................... 351
    9.4.2 Antioxidant, Anti-inflammatory, and Antiexcitotoxic Strategies in PD ............ 351
    9.4.3 Stabilization of Mitochondrial Dynamics in PD .... 352
    9.4.4 Statins and PD Treatment ............................ 354
    9.4.5 Memantine and PD Treatment ........................ 355
9.4.6 PPAR Agonists and PD Treatment ................. 356
9.4.7 Neurotrophins and PD Treatment .................. 357
9.4.8 ω-3 Polyunsaturated Fatty Acids and PD Treatment . 357

9.5 Therapeutic Approaches for ALS ..................... 358
  9.5.1 Riluzole and Memantine and ALS Treatment ........ 359
  9.5.2 Antioxidant Strategies and ALS Treatment .......... 360
  9.5.3 Stabilization of Mitochondrial Dynamics and ALS Treatment ................................................. 360
  9.5.4 Neurotrophins and ALS Treatment .................. 361
  9.5.5 ω-3 Fatty Acids and ALS Treatment ................. 362
  9.5.6 Immunotherapy and ALS Treatment ................ 362

9.6 Therapeutic Approaches for HD .......................... 362
  9.6.1 Gene Silencing and HD Treatment .................. 363
  9.6.2 Enhancement of Protein Degradation and HD Treatment ......................................................... 363
  9.6.3 Inhibition of Aggregation and HD Treatment ......... 364
  9.6.4 Creatine and Other Antioxidants and HD Treatment ................. 364
  9.6.5 Minocycline and HD Treatment ..................... 365
  9.6.6 ω-3 Fatty Acids and HD Treatment ................ 365

9.7 Therapeutic Approaches for Prion Diseases ............. 366
  9.7.1 Pentosan Polysulfate for the Treatment of Prion Diseases ......................... 366
  9.7.2 Quinacrine for the Treatment of Prion Diseases .... 366
  9.7.3 Glimepiride for the Treatment of Prion Diseases .......... 368
  9.7.4 Vaccine for the Treatment of Prion Diseases .......... 368

9.8 Conclusion ........................................... 369

References .................................................. 370

10 Perspective and Direction for Future Developments on Neurotraumatic and Neurodegenerative Diseases ............... 383
  10.1 Introduction ........................................ 383
  10.2 Factors Contributing to Increased Frequency of Neurotraumatic and Neurodegenerative Diseases ............... 385
    10.2.1 Diet and Frequency of Occurrence of Neurotraumatic and Neurodegenerative Diseases ............... 386
    10.2.2 Detection of Neurotraumatic and Neurodegenerative Diseases .................................................. 387
  10.3 Proteomics and Lipidomics in Neurotraumatic and Neurodegenerative Diseases ................................ 388
  10.4 Vaccines for the Treatment of Neurotraumatic and Neurodegenerative Diseases ................................ 389
  10.5 Reasons for the Failure of Treatment in Neurotraumatic and Neurodegenerative Diseases ..................... 390
  10.6 Future Studies on the Treatment of Neurotraumatic and Neurodegenerative Diseases .......................... 391
  10.7 Conclusion ........................................... 393

References .................................................. 394

Index ...................................................... 399
Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases  
Farooqui, A.A.  
2010, XXIII, 401 p., Hardcover  
ISBN: 978-1-4419-6651-3